Vivos Therapeutics (VVOS) Total Liabilities (2019 - 2025)
Historic Total Liabilities for Vivos Therapeutics (VVOS) over the last 7 years, with Q3 2025 value amounting to $23.1 million.
- Vivos Therapeutics' Total Liabilities rose 20015.58% to $23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.1 million, marking a year-over-year increase of 20015.58%. This contributed to the annual value of $7.3 million for FY2024, which is 2896.6% down from last year.
- As of Q3 2025, Vivos Therapeutics' Total Liabilities stood at $23.1 million, which was up 20015.58% from $21.5 million recorded in Q2 2025.
- Vivos Therapeutics' 5-year Total Liabilities high stood at $23.1 million for Q3 2025, and its period low was $6.9 million during Q1 2025.
- Over the past 5 years, Vivos Therapeutics' median Total Liabilities value was $9.5 million (recorded in 2024), while the average stood at $10.5 million.
- The largest annual percentage gain for Vivos Therapeutics' Total Liabilities in the last 5 years was 20015.58% (2025), contrasted with its biggest fall of 3851.36% (2025).
- Vivos Therapeutics' Total Liabilities (Quarter) stood at $8.2 million in 2021, then rose by 9.44% to $8.9 million in 2022, then grew by 15.7% to $10.3 million in 2023, then fell by 28.97% to $7.3 million in 2024, then surged by 215.31% to $23.1 million in 2025.
- Its last three reported values are $23.1 million in Q3 2025, $21.5 million for Q2 2025, and $6.9 million during Q1 2025.